Login / Signup

Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.

Ieva PalubeckaitėSanne VennekerBrendy E W M van den AkkerInge H Briaire-de BruijnJudith V M G Bovée
Published in: Clinical orthopaedics and related research (2022)
Combination treatment of talazoparib and temozolomide was effective in reducing the viability of chondrosarcoma spheroids and spheroid growth, regardless of IDH mutation status, providing rationale to replicate this treatment combination in an animal chondrosarcoma model.
Keyphrases
  • early stage
  • locally advanced
  • clinical trial
  • stem cells
  • squamous cell carcinoma
  • oxidative stress
  • combination therapy
  • dna repair
  • mesenchymal stem cells
  • high grade
  • newly diagnosed